Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
11.98
+0.08 (0.67%)
At close: May 15, 2026, 4:00 PM EDT
12.00
+0.02 (0.17%)
After-hours: May 15, 2026, 7:58 PM EDT
Tenax Therapeutics Employees
As of December 31, 2025, Tenax Therapeutics had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 10 or 166.67% compared to the previous year.
Employees
16
Change (1Y)
10
Growth (1Y)
166.67%
Revenue / Employee
n/a
Profits / Employee
-$3,619,188
Market Cap
705.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | 10 | 166.67% | 14 | 2 |
| Dec 31, 2024 | 6 | 0 | - | 4 | 2 |
| Dec 31, 2023 | 6 | -2 | -25.00% | 5 | 1 |
| Dec 31, 2022 | 8 | -1 | -11.11% | 7 | 1 |
| Dec 31, 2021 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Allogene Therapeutics | 152 |
| Kyverna Therapeutics | 130 |
| Solid Biosciences | 121 |
| BridgeBio Oncology Therapeutics | 92 |
| Aclaris Therapeutics | 73 |
| Zevra Therapeutics | 61 |
| Candel Therapeutics | 55 |
TENX News
- 3 days ago - Tenax Therapeutics reports Q1 EPS (35c), consensus (40c) - TheFly
- 3 days ago - Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 days ago - Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - Tenax Therapeutics appoints Timothy Healey as chief commercial officer - TheFly
- 11 days ago - Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer - GlobeNewsWire
- 23 days ago - Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer - GlobeNewsWire
- 7 weeks ago - Four new option listings on March 25th - TheFly
- 7 weeks ago - Tenax Therapeutics files $300M mixed securities shelf - TheFly